Articles by Shim Woo-hyun
Shim Woo-hyun
ws@heraldcorp.com-
Samsung Bioepis posts record-high biosimilar sales
Overseas biosimilar sales of Samsung Bioepis, a biosimilar developer under Samsung Group, reached an all-time high in 2023, according to its partner companies on Sunday. According to Samsung Bioepis’ US partners, Biogen and Organon, sales of Samsung Bioepis’ biosimilar products in overseas markets came to $1.36 billion, or some 1.8 trillion won in 2023. The figure was up 11 percent from $1.23 billion in 2022. Biosimilar sales through Biogen came to $770 million, up 3 percent on-year,
Industry Feb. 18, 2024
-
LG Chem, CJ CheilJedang to partner on bio-based nylon
LG Chem announced Thursday that the company will work together with food giant CJ CheilJedang to produce bio-based nylon, an eco-friendly alternative to traditional synthetic polymers. LG Chem said the two companies signed a heads of agreement on Wednesday to establish a joint venture that will produce ingredients and bio-based nylon products. “It has not been determined yet, but the two companies are expected to establish the joint company as early as this year,” an official familia
Industry Feb. 15, 2024
-
Celltrion seeks approval for Actemra biosimilar in Europe
Celltrion announced Tuesday that the company has submitted its application for marketing authorization to the European Medicines Agency for CT-P47, a biosimilar referencing Roche's Actemra. Roche's Actemra (tocilizumab) is approved for a wide range of uses, including rheumatoid arthritis, giant cell arteritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis and cytokine release syndrome. Celltrion’s application has been based on the results from a glob
Industry Feb. 13, 2024
-
Inexpensive whiskey brands target Korean budget sippers
South Korean whiskey providers are searching for new import markets like those in Taiwan, India, Spain and Australia, as consumers here crave new varieties at reasonable prices. “Local demands for affordable whiskey products are increasing with the surge of people consuming highball cocktails. Yet, whiskey products from major whiskey producers such as the UK, the US and Japan are expensive and less available to local consumers,” an industry source said. “Whiskey products from A
Consumer Feb. 11, 2024
-
Untamed food prices eclipse Seollal
A better-than-expected inflation report for January bolstered hopes that price hikes is near its end -- but consumers are still wary as the cost for some food items for Lunar New Year ceremonies continues to soar. “I have visited two different discount stores and searched online shopping platforms to compare prices and buy cheaper fruits and other food items that I need for family gatherings during the Lunar New Year holiday,” Lee, 63, a woman living in Gyeonggi Province said. Among
Consumer Feb. 9, 2024
-
Former Posco CEO named as group’s next chairman
Posco Holdings said Thursday it has named Chang In-hwa, former CEO of steelmaker Posco, to lead the nation's fifth-largest business group as its next chairman. The result was announced after seven members of the CEO Candidate Recommendation Committee of Posco Group interviewed six candidates in the final list on Wednesday and Thursday. If approved at the group’s annual general meeting of shareholders and board meeting on March 21, Chang will be appointed as chairman of the country&rsq
Industry Feb. 8, 2024
-
Conglomerates hesitant to hire
South Korean conglomerates are becoming more reluctant to finalize their hiring plans this year or downsize the number of new employees as their business prospects are shrouded in uncertainty, a poll on job recruiters showed on Thursday. Some 67 percent of conglomerates with over 1,000 employees confirmed that they have recruitment plans this year, falling for the third year in a row from 72 percent and 73 percent in 2023 and 2022, respectively, according to a report by online job portal Incruit
Industry Feb. 8, 2024
-
GNT Pharma partners with Pfizer for animal drug development
GNT Pharma said Monday that the company has signed an agreement with Pfizer's contract manufacturing arm for overseas production of the company’s veterinary medication GedaCure. Under the recent agreement, Pfizer CentreOne, which has production facilities in around 30 countries, will provide GNT Pharma with CDMO services in the countries, including the US and Europe, where GNT Pharma launches GedaCure. GedaCure is a chewable tablet of crisdesalazine and the world’s first multi-t
Industry Feb. 5, 2024
-
Korean dietary supplements makers eye Chinese market
South Korean dietary supplements manufacturers are accelerating their entries into the growing Chinese market as the number of elderly people continues to increase in the country, according to industry sources on Sunday. On the back of an aging population, the Chinese dietary supplements market grew 3 percent on-year to reach around 73 trillion won ($54.5 billion) in 2022, according to a report released by the Korea Trade-Investment Promotion Agency. Among Korean companies, Korea Ginseng Corp.,
Consumer Feb. 4, 2024
-
BAT names new Korean chief
BAT Rothmans, the Korean unit of British American Tobacco, announced Thursday that the company has appointed Song Young-jae, a BAT veteran, as its new country manager. The company said Song is a marketing and finance expert who will be tasked with promoting BAT’s combustible products. “Song is an expert in the global tobacco industry and the right person to spearhead the company’s future innovation,” an official from BAT Rothmans said. Graduated from the London School of
Industry Feb. 1, 2024
-
Kakao Healthcare plans to debut diabetes app in Japan
Kakao Healthcare, the digital health care unit under platform giant Kakao, on Thursday launched an artificial intelligence-based mobile blood sugar management service, PASTA, in Korea, hinting at plans for its overseas debuts in Japan and other countries. “Health care costs attributable to diabetes are increasing every year, and we aim to help reduce the costs through our new service," Kakao Healthcare CEO Hwang Hee said during a press conference at the company’s headquarters in
Industry Feb. 1, 2024
-
Posco, ADNOC to produce blue hydrogen in Gwangyang
Posco Group and the United Arab Emirates' Abu Dhabi National Oil Company will collaborate on blue hydrogen production facilities in Gwangyang, South Jeolla Province, Posco International said Wednesday. Posco International, Posco Holdings and ADNOC signed a three-way strategic collaboration agreement at the UAE energy group’s headquarters in Abu Dhabi. Under the agreement, the three companies will build blue hydrogen production facilities at Posco International’s liquefied natura
Industry Jan. 31, 2024
-
Samsung Biologics stocks extend rally on US bill
Samsung Biologics shares extended a rally Tuesday on upbeat sentiment that the company may be benefiting from US-proposed legislation that aims to restrict Chinese biotech firms from accessing the all-important American market. Last week, members of a bipartisan House Select Committee introduced a bill barring contracts with Beijing Genomics Institute and some Chinese biotech companies for their alleged connection with China’s People’s Liberation Army. The proposed bill specifically
Industry Jan. 30, 2024
-
[Herald Interview] Daewoong Pet targets health-conscious pet owners
Daewoong Pet, the pet health care arm of Daewoong Pharmaceutical, seeks to gain growth momentum by launching veterinary drugs and securing patent exclusivity as the need for veterinary care continues to surge amid an aging pet population. The firm's main aim is to develop and introduce drugs with the proper dosage and formulation for pets, with a particular focus on senior pets, which increasingly require health care services, Daewoong Pet co-CEO Lee Hyo-jun said. “Many veterinary hos
Industry Jan. 30, 2024
-
Celltrion seeks FDA approval for Actemra biosimilar
Celltrion has completed its submission of a biologics license application (BLA) to the US Food and Drug Administration for CT-P47, a biosimilar candidate mimicking Roche’s rheumatoid arthritis treatment Actemra (tocilizumab), the company said Monday. The BLA submission was based on results from the global phase 3 clinical trial involving 471 patients. In the clinical trial, the company tested the efficacy, pharmacokinetics, safety, and immunogenicity of CT-P47 compared to the reference pro
Industry Jan. 29, 2024
Most Popular
-
1
What is South Korea’s 4B movement?
-
2
Actor Song Jae-rim dies at 39
-
3
Dialogue launches without junior doctors, main opposition
-
4
LG eyes footing in aerospace with possible SpaceX deal
-
5
'Are you a T?' is a new put-down in S. Korea
-
6
Seoul to begin UAM demonstration services in 2025
-
7
[Herald Interview] JobKorea’s Klik brings jobs, community to growing foreign workforce in Korea
-
8
Bitcoin hits record in Korea, even without ‘kimchi premium’
-
9
Push for Seoul getting own nuclear arms gains steam after Trump win
-
10
[Graphic News] Rising wedding costs raise cash gift expectations